NASDAQ$TECX
Tectonic Therapeutic Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
AVROBIO reported a net loss for the second quarter of 2022, driven by a reduction in research and development expenses, while highlighting pipeline advancements and upcoming milestones.
AVROBIO reported a net loss of $28.1 million for Q2 2022, with reduced research and development expenses. The company is advancing its gene therapy pipeline, with key milestones expected in the second half of the year, including regulatory interactions and clinical data updates for cystinosis and Gaucher disease programs.
- Presented positive data from Phase 1/2 cystinosis trial, showing systemic gene therapy effect.
- Comprehensive Gaucher disease franchise update planned for Q4 2022.
- Regulatory interactions planned in 2H 2022 to inform clinical development strategies for cystinosis and Gaucher disease type 3.
- Cash runway extended into Q1 2024.
Headline financials
Revenue & EPS history
Tectonic · Revenue · Quarterly
$0
Forward guidance
AVROBIO plans to engage with regulatory agencies in the second half of 2022 to discuss clinical development and regulatory strategies for cystinosis and Gaucher disease, with the aim of initiating company-sponsored clinical trials in 2023. Additionally, a clinical trial application authorization is expected for Hunter syndrome, with plans to initiate a collaborator-sponsored Phase 1/2 clinical trial in 2023.
Tailwinds
- Plan to engage with regulatory agencies in 2H 2022 to discuss clinical development and regulatory strategy for cystinosis.
- Aim to initiate a company-sponsored clinical trial in 2023 for cystinosis, subject to regulatory alignment.
- Plan to provide interim clinical data update for Gaucher disease type 1 in 2H 2022.
- Aim to initiate a trial in 2023 for Gaucher disease type 3, subject to regulatory alignment.
- Clinical Trial Application (CTA) authorization expected 2H 2022 for Hunter syndrome.
Headwinds
- Initiation of clinical trials is subject to regulatory alignment.
- Clinical trial plans are dependent on collaborator progress.
- Future results may differ materially and adversely from forward-looking statements.
- Success of product candidates is subject to risks and uncertainties.
- Dependence on third-party suppliers and manufacturers poses risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2022
-1.4%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+2.9%
Avg return
30 days after
41%
7 / 17 earnings
Positive
+11.1%
Q4 2021
Best reaction
-20.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.4% | +14.5% | +22.6% | |
| Q3 2025 | +1.5% | -0.7% | +4.9% | |
| Q1 2025 | -0.9% | +3.5% | -13.4% | |
| Q4 2024 | +1.0% | -11.8% | +11.0% | |
| Q3 2024 | -2.0% | +6.5% | +14.8% | |
| Q1 2024 | +0.0% | -0.8% | -7.0% | |
| Q4 2023 | +0.8% | -2.3% | -1.6% | |
| Q3 2023 | -9.9% | -13.2% | -7.2% | |
| Q2 2023 | +0.6% | -1.9% | +4.5% | |
| Q1 2023 | -4.5% | -4.5% | +82.1% | |
| Q4 2022 | -20.3% | -14.6% | -23.6% | |
| Q3 2022 | -1.5% | +12.1% | +19.7% | |
| Q2 2022 | +5.0% | +5.9% | -12.9% | |
| Q1 2022 | -7.3% | -1.2% | +30.5% | |
| Q4 2021 | +11.1% | +12.5% | -20.8% | |
| Q3 2021 | -1.0% | -3.8% | -40.7% | |
| Q2 2021 | +6.5% | -17.0% | -13.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro